Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843Phase 2Active, not recruiting
- Start
- Sep 2020
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of eflornithine in neuroblastoma (3 arms). Primary endpoint: Event-Free Survival at 7 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
eflornithine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04301843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301843.